We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+21.73%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.55B
AUM Growth
+$969M
Cap. Flow
+$774M
Cap. Flow %
49.87%
Top 10 Hldgs %
88.53%
Holding
32
New
3
Increased
3
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
VTI icon
Vanguard Total Stock Market ETF
VTI
+$678M
2
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$41.6M
3
BN icon
Brookfield
BN
+$37.6M
4
CABO icon
Cable One
CABO
+$26.9M
5
SPRO icon
Spero Therapeutics
SPRO
+$5.02M

Top Sells

Rank Stock Value
1
KIDS icon
OrthoPediatrics
KIDS
+$5.33M
2
XLRN
Acceleron Pharma
XLRN
+$4.73M
3
MIST icon
Milestone Pharmaceuticals
MIST
+$4.25M
4
COGT icon
Cogent Biosciences
COGT
+$682K

Sector Composition

Rank Sector Weight
1 Healthcare 37.72%
2 Communication Services 6.13%
3 Technology 5.06%
4 Financials 2.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$655B
$708M 45.58%
+4,325,200
New +$678M
INGN icon
2
Inogen
INGN
$171M
$243M 15.62%
3,549,321
– –
CABO icon
3
Cable One
CABO
$224M
$95.2M 6.13%
63,947
+18,947
+42% +$26.9M
AAPL icon
4
Apple
AAPL
$4.95T
$78.6M 5.06%
1,071,152
– –
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.96B
$60M 3.86%
2,445,147
– –
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$45.4M 2.92%
2,645,446
– –
GRTX
7
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$44.9M 2.89%
+3,409,021
New +$41.6M
MIST icon
8
Milestone Pharmaceuticals
MIST
$141M
$39M 2.51%
2,434,470
-240,000
-9% -$4.25M
BN icon
9
Brookfield
BN
$103B
$38.9M 2.5%
+1,885,264
New +$37.6M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$22.6M 1.45%
2,317,870
– –
AKBA icon
11
Akebia Therapeutics
AKBA
$343M
$19.6M 1.26%
3,100,000
– –
SIBN icon
12
SI-BONE Inc
SIBN
$756M
$19.2M 1.24%
892,684
– –
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
$16.2M 1.04%
670,036
– –
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$1.09B
$15.9M 1.03%
2,927,560
– –
SPNE
15
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$15.7M 1.01%
1,308,037
– –
BPMC
16
DELISTED
Blueprint Medicines
BPMC
$13.7M 0.88%
170,667
– –
INSP icon
17
Inspire Medical Systems
INSP
$1.47B
$13M 0.84%
175,000
– –
ETTX
18
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$10.8M 0.7%
2,181,843
– –
SILK
19
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$9.89M 0.64%
245,000
– –
SPRO icon
20
Spero Therapeutics
SPRO
$68.3M
$8.95M 0.58%
931,099
+465,116
+100% +$5.02M
XENT
21
DELISTED
Intersect ENT, Inc
XENT
$5.42M 0.35%
217,709
– –
VRNA
22
DELISTED
Verona Pharma
VRNA
$4.26M 0.27%
740,740
– –
CRNX icon
23
Crinetics Pharmaceuticals
CRNX
$8.87B
$3.39M 0.22%
135,009
– –
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.72B
$3.38M 0.22%
479,074
– –
STIM icon
25
Neuronetics
STIM
$126M
$3.31M 0.21%
736,578
+108,230
+17% +$672K
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q4 2019 Portfolio in Review

As of Q4 2019, Novo Holdings A/S held 32 positions worth $1.55B, up 166% from $584M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Novo Holdings A/S deployed $774M of net new capital in Q4 2019, opening 3 new positions and adding to 3 existing holdings. Its largest new stake was Vanguard Total Stock Market ETF: 4,325,200 shares worth $708M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 73% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Milestone Pharmaceuticals, an estimated $4.25M trimmed.

  • Novo Holdings A/S's largest Q4 2019 buy was Vanguard Total Stock Market ETF: 4,325,200 shares worth $708M.
  • Novo Holdings A/S added most to Cable One in Q4 2019, an estimated $26.9M increase.
  • Novo Holdings A/S's biggest Q4 2019 reduction was Milestone Pharmaceuticals, cutting an estimated $4.25M.
  • Novo Holdings A/S fully exited OrthoPediatrics in Q4 2019, selling an estimated $5.33M.
  • Novo Holdings A/S's ten largest holdings make up 89% of its $1.55B portfolio in Q4 2019.
  • Novo Holdings A/S opened 3 new positions and closed 3 in Q4 2019.
  • Novo Holdings A/S's portfolio value rose 166% quarter-over-quarter to $1.55B.

Based on Novo Holdings A/S's 13F filing for Q4 2019, filed 14 Feb 2020.